Pivotal Data Boost Omeros’ Stem Cell Transplant Product After FDA Delay
Narsoplimab Likely To Be First Drug For Treating HSCT-TMA
• By Sten Stovall
Omeros announced results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy • Source: Alamy
Keep up with the top pharma business news of the week. On the go.
